Abstract: The present invention is directed to a personal care composition comprising a) azoxystrobin; b) a 2-pyridinol-N-oxide material wherein the ratio of a:b is from about 4:1 to about 1:50; wherein there is a synergistic anti-inflammatory/cellular stress activity.

Abstract: The present invention discloses to a personal care composition having a polyvalent metal salt of pyrithione; a 2-pyridinol-N-oxide material; and a zinc containing layered material; wherein the ratio of a:b is from about 0.5 to about 1.5; the ratio of b:c is about 0.2 to about 1.0; and the ratio of a:c is about 0.2 to about 1.0 and wherein there is a synergistic antioxidant activity.

Abstract: This disclosure relates to a supplement, particularly a supplement for menopause.

Abstract: A method of treating vaginal atrophy is provided. The method comprises administering a vaginal care composition to vaginal tissue of a user experiencing a symptom of vaginal atrophy. The vaginal care composition may include an effective amount of a vaginal care agent selected to specifically treat symptoms of vaginal atrophy exhibited by the introitus and/or labia, based on the transcriptomic data of skin cells obtained therefrom. In some instances, the vaginal care composition may be applied to introitus and/or labia with a suitable implement configured for such use.

Abstract: A method of treating vaginal dryness by administering a vaginal care composition, which includes an effective amount of a vaginal care agent, to vaginal tissue of a user experiencing vaginal dryness. The vaginal care agent may be selected to specifically treat symptoms of vaginal dryness exhibited by the introitus and/or labia, based on the transcriptomic data of skin cells obtained therefrom. In some instances, the vaginal care composition may be applied to introitus and/or labia with a suitable implement configured for such use.

Abstract: Methods and compositions for improving the appearance of skin are provided. The methods and compositions are especially suited for inhibiting activation of PAR2 in skin by utilizing a synergistic combination of a water lily extract and vitamin B3 compound. The method involves treating hyperpigmented skin by applying a skin care composition containing an effective amount of a combination of water lily extract and vitamin B3 compound to a target portion of skin over the course of a treatment period.

Abstract: This disclosure relates to a supplement, particularly a supplement for menopause.

Abstract: This disclosure relates to a supplement, particularly a supplement for menopause.

Abstract: Treatment for excess adipose tissue by applying an activating compound directly to a targeted area. The activating compound is a cyclohexanecarboxamide derivative. The activating compound promotes thermogenesis in cells to generate heat.

Abstract: An improved method of treating a skin barrier condition is disclosed. The method involves identifying a target portion of skin on a person where treatment is desired and applying a low-pH composition to the target portion of skin. The low-pH composition contains an effective amount of a vitamin B3 compound and has a pH of less than 5.0.

Abstract: An improved connectivity mapping method for identifying connections between a potential skin care agent associated with an instance and genes associated with a skin hyperpigmentation condition. The system includes a non-transitory computer readable medium having a plurality of instances stored thereon, and a biased gene expression signature associated with a skin condition. The biased condition signature is constructed by filtering an unbiased condition signature through a benchmark signature.

Abstract: The present invention discloses to a personal care composition having a polyvalent metal salt of pyrithione; a 2-pyridinol-N-oxide material; and a zinc containing layered material; wherein the ratio of a:b is from about 0.5 to about 1.5; the ratio of b:c is about 0.2 to about 1.0; and the ratio of a:c is about 0.2 to about 1.0 and wherein there is a synergistic antioxidant activity.

Abstract: Embodiments of screening methods for determining test agents effective for modifying the appearance of pigmented skin are provided. The screening method may comprise the steps of contacting a cell, a cell culture, or bulk cells with the test agent, wherein the cell, the cell culture, or the bulk cells comprise ADR?1 receptors, and determining based on the binding interaction of the test agent with the ADR?1 receptors whether the test agent is an effective ADR?1 receptor antagonist suitable for modifying the appearance of pigmented skin, wherein a test agent is considered to be an effective ADR?1 receptor antagonist when it defines a half maximal inhibitory concentration of less than about 1000 ppm.

Abstract: A method of identifying a test agent as a skin tone agent. The method includes determining the level of high-mobility group protein B1 (HMGB1), messenger RNA associated with the expression and/or regulation of HMGB1 (HMGB1 mRNA), and/or micro-RNA associated with the expression and/or regulation of HMGB1 (HMGB1 miRNA) present in the test sample, and identifying the test agent as a skin tone agent when there is no increase in HMGB1 level, a downregulation in transcription of HMGB1 mRNA, and/or an upregulation of HMGB1 miRNA. The method also includes identifying a test agent as a skin tone agent when the test agent inhibits or prevents an increase in melanocyte dendricity and/or body size caused by HMGB1.

Abstract: A method of making a skin composition that includes an effective amount of skin care agent selected to inhibit HMGB1 stimulation of human melanocytes. The method includes determining the level of high-mobility group protein B1 (HMGB1), messenger RNA associated with the expression and/or regulation of HMGB1 (HMGB1 mRNA), and/or micro-RNA associated with the expression and/or regulation of HMGB1 (HMGB1 miRNA) present in the test sample, and identifying the test agent as a skin tone agent when there is no increase in HMGB1 level, a downregulation in transcription of HMGB1 mRNA, and/or an upregulation of HMGB1 miRNA. The method also includes identifying a test agent as a skin tone agent when the test agent inhibits or prevents an increase in melanocyte dendricity and/or body size caused by HMGB1, and incorporating the skin tone agent in a dermatologically acceptable carrier.

Abstract: A cosmetic composition suitable for topical application, for example, is provided. In some examples, the cosmetic composition may include bisabolol, undecylenoyl phenylalanine and/or hexyldecanol, and a material selected from the group consisting of ethyl palmitate, stearyl alcohol, bis (2-ethylhexyl) adipate, bis (2-ethylhexyl) maleate, 5-pentadecanol, 1-stearoyl-rac-glycerol, bis (2-ethylhexyl) sebacate, and mixtures thereof. A method of reducing the synthesis of melanin by using the cosmetic compositions is also disclosed herein.

Abstract: A cosmetic composition for topical application to skin is provided. The cosmetic composition includes vitamin B3 compound, a ricinoleate compound and a dermatologically acceptable carrier. The vitamin B3 compound and the ricinoleate beneficially or even synergistically up-regulate proteasomal protease activity as evidenced by a higher observed net luminescence value relative to the calculated net luminescence value in B16 melanoma cells.

Abstract: A cosmetic composition suitable for topical application, for example, is provided. In some examples, the cosmetic composition may include batyl alcohol, undecylenoyl phenylalanine, hexyldecanol, and bisabolol. A method of reducing the synthesis of melanin by using the cosmetic compositions is also disclosed herein.

Abstract: Cosmetic methods of increasing ARE activated gene transcription in a skin cell by contacting skin cells in a target portion of skin with an effective amount of niacinamide and nicotinamide riboside in combination to increase ARE activated gene transcription or synergistically increase ARE activated gene transcription of at least some of the skin cells contacted with the niacinamide and nicotinamide riboside. The cosmetic methods also enable synergistic reduction of ROS-induced adenosine triphosphate (ATP) depletion in a skin cell and restoration of glycolytic ATP production rate in a skin cell that has been reduced as a result of ROS-induced oxidative stress.

Abstract: A cosmetic method for reducing glycation rate in skin by topically applying a cosmetic composition that includes an effective amount of nicotinamide riboside to a target portion of skin during a treatment period. The treatment period is sufficient for the nicotinamide riboside containing composition to improve the appearance of sallow-looking skin caused by glycation. In particular, the method enables a reduction in skin yellowness related to glycation.